- Home
- EPSM vs GOSS Comparison
EPSM vs GOSS Comparison
Compare EPSM & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSM
- GOSS
- Stock Information
- Founded
- EPSM 2010
- GOSS 2015
- Country
- EPSM China
- GOSS United States
- Employees
- EPSM N/A
- GOSS N/A
- Industry
- EPSM
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- EPSM
- GOSS Health Care
- Exchange
- EPSM Nasdaq
- GOSS Nasdaq
- Market Cap
- EPSM 333.5M
- GOSS 347.8M
- IPO Year
- EPSM 2025
- GOSS 2019
- Fundamental
- Price
- EPSM $23.70
- GOSS $2.46
- Analyst Decision
- EPSM
- GOSS Strong Buy
- Analyst Count
- EPSM 0
- GOSS 4
- Target Price
- EPSM N/A
- GOSS $8.50
- AVG Volume (30 Days)
- EPSM 530.3K
- GOSS 3.0M
- Earning Date
- EPSM 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- EPSM N/A
- GOSS N/A
- EPS Growth
- EPSM N/A
- GOSS N/A
- EPS
- EPSM 0.02
- GOSS N/A
- Revenue
- EPSM $12,518,070.00
- GOSS $40,237,000.00
- Revenue This Year
- EPSM N/A
- GOSS N/A
- Revenue Next Year
- EPSM N/A
- GOSS $30.65
- P/E Ratio
- EPSM $1,195.39
- GOSS N/A
- Revenue Growth
- EPSM N/A
- GOSS N/A
- 52 Week Low
- EPSM $4.23
- GOSS $0.66
- 52 Week High
- EPSM $29.76
- GOSS $2.64
- Technical
- Relative Strength Index (RSI)
- EPSM N/A
- GOSS 70.68
- Support Level
- EPSM N/A
- GOSS $1.88
- Resistance Level
- EPSM N/A
- GOSS $2.03
- Average True Range (ATR)
- EPSM 0.00
- GOSS 0.15
- MACD
- EPSM 0.00
- GOSS 0.04
- Stochastic Oscillator
- EPSM 0.00
- GOSS 81.12
About EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.